Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Boston’s Regenta Raises $52 Million for RNA Drugs from China Investors

publication date: Dec 1, 2022

Rgenta Therapeutics, a Cambridge, Mass. company developing RNA drugs for currently unavailable targets, closed a $52 million Series A round from mostly China investors. The company is building a portfolio of oncology and neurology candidates. Its discovery platform analyzes large amounts of human genomics data to identify targetable RNA processing events and then it designs small-molecule glues to modulate the interactions between the spliceosome, regulatory proteins and RNA. The A Round was led by AZ-CICC Healthcare Investment Fund, a Joint Venture between AstraZeneca and China’s CICC Capital. More details....

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital